Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Leavitt

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Advances in Experimental Medicine and Biology|January 1, 1993
Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosisG S Kerr, T A Fleisher, C W Hallahan, et al.
The Journal of Pediatrics|January 1, 1993
Wegener granulomatosis in children and adolescents: clinical presentation and outcomeM Rottem, A S Fauci, C W Hallahan, et al.
Annals of Internal Medicine|June 1, 1994
Takayasu arteritisG S Kerr, C W Hallahan, J Giordano, et al.
AIDS (London, England)|August 16, 2001
Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trialsP M Coplan, A A Nikas, R Y Leavitt, et al.
American Journal of Respiratory and Critical Care Medicine|March 1, 1995
Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosisF P Ognibene, J H Shelhamer, G S Hoffman, et al.
Open Forum Infectious Diseases|March 4, 2015
Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without AdjuvantsErin K Quirk, Elizabeth L Brown, Randi Y Leavitt, et al.
Annals of Internal Medicine|March 15, 1992
Wegener granulomatosis: an analysis of 158 patientsG S Hoffman, G S Kerr, R Y Leavitt, et al.
The Laryngoscope|December 1, 1992
The management of subglottic stenosis in patients with Wegener's granulomatosisR S Lebovics, G S Hoffman, R Y Leavitt, et al.
AIDS (London, England)|April 28, 2011
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studiesJürgen K Rockstroh, Hedy Teppler, Jing Zhao, et al.
Open Forum Infectious Diseases|May 9, 2017
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK StudiesKathleen Squires, Linda-Gail Bekker, Christine Katlama, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Advances in Experimental Medicine and Biology|January 1, 1993
Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosisG S Kerr, T A Fleisher, C W Hallahan, et al.
The Journal of Pediatrics|January 1, 1993
Wegener granulomatosis in children and adolescents: clinical presentation and outcomeM Rottem, A S Fauci, C W Hallahan, et al.
Annals of Internal Medicine|June 1, 1994
Takayasu arteritisG S Kerr, C W Hallahan, J Giordano, et al.
AIDS (London, England)|August 16, 2001
Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trialsP M Coplan, A A Nikas, R Y Leavitt, et al.
American Journal of Respiratory and Critical Care Medicine|March 1, 1995
Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosisF P Ognibene, J H Shelhamer, G S Hoffman, et al.
Open Forum Infectious Diseases|March 4, 2015
Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without AdjuvantsErin K Quirk, Elizabeth L Brown, Randi Y Leavitt, et al.
Annals of Internal Medicine|March 15, 1992
Wegener granulomatosis: an analysis of 158 patientsG S Hoffman, G S Kerr, R Y Leavitt, et al.
The Laryngoscope|December 1, 1992
The management of subglottic stenosis in patients with Wegener's granulomatosisR S Lebovics, G S Hoffman, R Y Leavitt, et al.
AIDS (London, England)|April 28, 2011
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studiesJürgen K Rockstroh, Hedy Teppler, Jing Zhao, et al.
Open Forum Infectious Diseases|May 9, 2017
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK StudiesKathleen Squires, Linda-Gail Bekker, Christine Katlama, et al.
Pageof 6